Neon Therapeutics Inc (NASDAQ:NTGN) was up 11.3% during mid-day trading on Tuesday . The stock traded as high as $2.71 and last traded at $2.66, approximately 207,638 shares changed hands during mid-day trading. An increase of 28% from the average daily volume of 162,447 shares. The stock had previously closed at $2.39.

Several equities analysts have issued reports on NTGN shares. Morgan Stanley decreased their price objective on shares of Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating for the company in a research note on Tuesday, July 16th. Mizuho set a $21.00 price objective on shares of Neon Therapeutics and gave the company a “buy” rating in a research note on Monday, July 1st. Zacks Investment Research downgraded shares of Neon Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 16th. ValuEngine upgraded shares of Neon Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Robert W. Baird started coverage on shares of Neon Therapeutics in a research note on Thursday, July 25th. They issued an “outperform” rating and a $15.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $14.43.

The stock has a market capitalization of $75.49 million, a PE ratio of -0.48 and a beta of 1.62. The business has a fifty day moving average price of $3.68. The company has a quick ratio of 6.13, a current ratio of 6.13 and a debt-to-equity ratio of 0.12.

Neon Therapeutics (NASDAQ:NTGN) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.01). On average, equities research analysts predict that Neon Therapeutics Inc will post -2.55 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of NTGN. BlackRock Inc. raised its position in shares of Neon Therapeutics by 12.0% during the 4th quarter. BlackRock Inc. now owns 307,782 shares of the company’s stock valued at $1,548,000 after buying an additional 32,943 shares during the period. Bank of New York Mellon Corp raised its position in shares of Neon Therapeutics by 17.6% during the 4th quarter. Bank of New York Mellon Corp now owns 19,427 shares of the company’s stock valued at $98,000 after buying an additional 2,905 shares during the period. Northern Trust Corp raised its position in shares of Neon Therapeutics by 68.9% during the 4th quarter. Northern Trust Corp now owns 88,678 shares of the company’s stock valued at $446,000 after buying an additional 36,170 shares during the period. Geode Capital Management LLC raised its position in shares of Neon Therapeutics by 127.0% during the 4th quarter. Geode Capital Management LLC now owns 60,309 shares of the company’s stock valued at $303,000 after buying an additional 33,741 shares during the period. Finally, Bank of America Corp DE raised its position in shares of Neon Therapeutics by 42.7% during the 4th quarter. Bank of America Corp DE now owns 21,712 shares of the company’s stock valued at $109,000 after buying an additional 6,493 shares during the period. 69.53% of the stock is owned by hedge funds and other institutional investors.

About Neon Therapeutics (NASDAQ:NTGN)

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Featured Article: Can systematic risk be avoided?

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.